Should we tolerate tolerability as an objective in early drug development?
Open Access
- 16 August 2007
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (3) , 249-252
- https://doi.org/10.1111/j.1365-2125.2007.03023.x
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Homeopathy is safe and does not lack positive evidence in clinical trialsBritish Journal of Clinical Pharmacology, 2007
- Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal womenBritish Journal of Clinical Pharmacology, 2007
- Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic painBritish Journal of Clinical Pharmacology, 2007
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Scottish GPs use of homeopathyBritish Journal of Clinical Pharmacology, 2007
- Inquiry into adverse events in trial blames drug, not study designBMJ, 2006
- Learning from the TGN1412 trialBMJ, 2006
- Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Ximelagatran in Young Healthy Japanese MenClinical Pharmacokinetics, 2006
- Joining the DoTS: new approach to classifying adverse drug reactionsBMJ, 2003
- Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarctionAmerican Heart Journal, 1998